Articles

UPDATE: Pipeline challenges force Lilly restructuring moves

Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.

Read More

Lilly reorganization to cut 5,500 positions over 2 years

Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.

Read More

Lilly drops osteoporosis pipeline drug

Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating
the company’s attempts to find revenue before losing patent protection on its bestseller.

Read More

Lilly taps hedge fund to cut research costs for Alzheimer’s drugs

Eli Lilly and Co.’s unorthodox efforts to develop new treatments for Alzheimer’s disease–if successful–could usher in
a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York
hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs
of two experimental compounds to treat Alzheimer’s disease.

Read More

Lilly still breathing in inhaler pursuit

Pfizer Inc.’s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open
for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer’s troubles might cause
doctors and patients to sour on all inhaled insulin products.

Read More

Lilly decides to self-insure for product liability

Eli Lilly and Co. has picked an insurer it knows extremely well to cover future problems in the high-stakes world of product liability litigation–itself. The Indianapolis drugmaker opted for self-insurance after struggling to find coverage in what it terms a “very restrictive insurance market.”

Read More